Our Science: Transforming Drug Delivery for Next-Generation Therapeutics

At the core of BioNxt Solutions is a technology-first approach to therapeutic innovation. We specialize in the development of proprietary drug delivery platforms designed to optimize pharmacokinetics, improve therapeutic precision, and enhance patient outcomes across a range of complex diseases.

Our R&D efforts focus on three key pillars: sublingual thin films and transdermal systems for improved systemic delivery, a targeted chemotherapy platform for localized cancer treatment with minimized toxicity, and a proprietary library of next-generation psychedelic compounds for personalized care in mental health and inflammation.

Supported by a strong intellectual property portfolio and GMP-compliant infrastructure in Germany, our scientific platform enables faster development, repurposing of known compounds, and scalable manufacturing. We are not just developing new treatments—we are building the drug delivery architecture for the future of care.

Core Focus Areas

1. Advanced Drug Delivery Systems
We develop proprietary sublingual thin-film (ODF) and transdermal patch technologies designed to improve bioavailability, enhance patient compliance, and support efficient treatment of neurological and other chronic diseases.

2. Targeted Chemotherapy Drug Delivery Platform
Our novel delivery system localizes cytotoxic activity inside tumors, reducing systemic toxicity and enhancing therapeutic precision. Compatible with over 100 chemotherapy agents, it offers a smarter, safer approach to cancer treatment.

3. Psychedelic Compound Library
We are developing a novel library of engineered psychedelic compounds designed to enable personalized treatment of neurological, psychiatric, and inflammatory conditions through optimized pharmacological profiles and delivery methods.

Product Pipeline

Our pipeline includes several promising candidates:

• BNT23001: A sublingual Cladribine film targeting multiple sclerosis (MS), offering improved bioavailability and patient convenience.
• BNT23002: A sublingual Cladribine formulation for myasthenia gravis (MG), addressing the challenges of oral medication in patients with swallowing difficulties.
• BNT24002: A sublingual thin film for the treatment of lupus nephritis (LN), aiming to enhance treatment efficacy and patient adherence.
• BNT24003: A sublingual thin film formulation for rheumatoid arthritis (RA), designed to improve compliance and therapeutic outcomes.
• BNT24004: A formulation targeting longevity and anti-aging, with early-stage evidence suggesting benefits such as slowing ovarian aging and promoting healthy aging.

Our commitment to innovation is backed by a robust intellectual property framework, securing our proprietary technologies in key global markets. By leveraging approved active pharmaceutical ingredients (APIs) and conducting bioequivalence studies, we aim to expedite time-to-market, significantly reducing development costs and regulatory hurdles..